Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

GOSS - Gossamer Bio, Inc. Последние новости | Finranks

Home

/

GOSS

G

Gossamer Bio, Inc. (GOSS)

NMS – Цена в реальном времени. Валюта: USD

0.18

-0.00 (-0.55%)

Рынок открыт: Aug 12, 2026, 12:40 PM EDT

0.18

-0.00 (-0.17%)

Предыдущая сессия: Aug 11, 2026, 7:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Gossamer Bio misrepresented or failed to disclose material information regarding its Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial hypertension (PAH).

Видео

No Data

There is no data to display

Пресс-релизы

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Gossamer Bio misrepresented or failed to disclose material information regarding its Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial hypertension (PAH).